Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026
Voyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue Estimates
Voyager Reports First Quarter 2026 Financial and Operating Results
Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease
Reviewing Longeveron (NASDAQ:LGVN) & Voyager Therapeutics (NASDAQ:VYGR)
Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
Voyager Therapeutics, Inc. (VYGR) Presents at Stifel 2026 Virtual CNS Forum Transcript
Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates
Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Voyager Therapeutics, Inc. (VYGR) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference Transcript
Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028
Voyager to Present at Upcoming Investor Conferences
Contrasting Voyager Therapeutics (NASDAQ:VYGR) and Alvotech (NASDAQ:ALVO)
Elixir begins mobilisation for Lorelle-3 as spud nears
Tamboran appoints Todd Abbott as CEO effective January 15
Fineqia’s Matteo Greco discusses crypto market trends - ICYMI
Immunic targets MS market with Phase 3 data - ICYMI
Arizona Gold & Silver CEO discusses latest high-grade drill results from Philadelphia project - ICYMI
Aftermath Silver secures 100% of Berenguela project - ICYMI
Genflow is ready for “a year of catalysts” - ICYMI
Ocean Power Technologies secures $5M US Coast Guard deal - ICYMI
Nextech3D.ai eyes growth with KraftyLab acquisition - ICYMI
American Resources secures $200M for ReElement Technologies scale-up: ICYMI
Seeing Machines CEO on accelerated royalties & profit path - ICYMI
Sintana Energy clarifies governance details on Challenger acquisition
Biotech outperformance expected to continue in 2026, Baird analysts say
Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
Voyager Reports Third Quarter 2025 Financial and Operating Results
Ethic Inc. Invests $123,000 in Voyager Therapeutics, Inc. $VYGR
Voyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock?
Voyager Therapeutics, Inc. (VYGR) Presents At Citi's Biopharma Back To School Conference Transcript
Voyager to Present at Upcoming Investor Conferences
Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates
Voyager Reports Second Quarter 2025 Financial and Operating Results
Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication
Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates
Voyager Reports First Quarter 2025 Financial and Operating Results
Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting
Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR
Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call Transcript
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Voyager Therapeutics, Inc. - VYGR